Mounjaro, which is available on the NHS, is one of the major brands associated with injectable weight loss medication and the most popular in the UK. However, Eli Lilly, the US-based manufacturer of Mounjaro, has announced that it is going to nearly double in price from September 1, to bring it in line with other nations. This is following intervention from President Trump who demanded that other countries stop “freeloading” off US firms. Since their announcement, it has been reported that Asda Online Doctor has seen a 350 per cent increase in demand, and London MedExpress has experienced a 40 per cent jump in orders. Sales of Ozempic, its cheaper counterpart, have risen by more than 500 per cent since the announcement.
Taking one of the prescribed semaglutide drugs, which naturally suppress appetite might sound like an easy shortcut to avoid falling off the weight loss wagon, but there are some dreadful side effects that come with the weekly self-administered pen injections. Nausea and vomiting are the most common symptoms but kidney and liver damage, gall bladder issues and pancreatitis are also harmful long-term side effects that some users experience, coupled with worries about piling back the pounds post-weaning off the medication. They can also cost around £300 a month.
